6-O-phosphono-D-glucono-1,5-lactone : An aldonolactone phosphate comprising D-glucono-1,5-lactone having the phosphate group at the 6-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 439452 |
| CHEBI ID | 16938 |
| SCHEMBL ID | 50310 |
| MeSH ID | M0140588 |
| Synonym |
|---|
| 6-o-phosphono-d-glucono-1,5-lactone |
| [(2r,3s,4s,5r)-3,4,5-trihydroxy-6-oxooxan-2-yl]methyl dihydrogen phosphate |
| d-gluconic acid, delta-lactone, 6-(dihydrogen phosphate) |
| CHEBI:16938 |
| [(2r,3s,4s,5r)-3,4,5-trihydroxy-6-oxotetrahydro-2h-pyran-2-yl]methyl dihydrogen phosphate |
| 6-phosphonoglucono-delta-lactone |
| 6-pgdl |
| delta-gluconolactone 6-phosphate |
| gluconic acid, delta-lactone, 6-(dihydrogen phosphate), d- (8ci) |
| d-gluconic acid, delta-lactone, 6-(dihydrogen phosphate) (9ci) |
| 6-phosphoglucono-delta-lactone |
| d-glucono-delta-lactone-6-phosphate |
| d-6-phosphoglucono-delta-lactone |
| C01236 |
| d-6-phospho-glucono-delta-lactone |
| d-glucono-1,5-lactone 6-phosphate |
| 2641-81-8 |
| 6-phospho-d-glucono-1,5-lactone |
| SCHEMBL50310 |
| {[(2r,3s,4s,5r)-3,4,5-trihydroxy-6-oxooxan-2-yl]methoxy}phosphonic acid |
| 6-phosphonoglucono-d-lactone |
| 6-(dihydrogen phosphate)-(8ci)-d-gluconic acid delta-lactone |
| 6-(dihydrogen phosphate)-d-gluconic acid delta-lactone |
| 6-(dihydrogen phosphate)-(9ci)-d-gluconic acid delta-lactone |
| Q245503 |
| ((2r,3s,4s,5r)-3,4,5-trihydroxy-6-oxotetrahydro-2h-pyran-2-yl)methyl dihydrogen phosphate |
| ((2r,3s,4s,5r)-3,4,5-trihydroxy-6-oxotetrahydro-2h-pyran-2-yl)methyldihydrogenphosphate |
| Role | Description |
|---|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| aldonolactone phosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||